Who is sponsoring NCT03671369?

NCT03671369 is sponsored by GlaxoSmithKline.

What condition does NCT03671369 study?

NCT03671369 studies Neoplasms, Rectal.

What drugs are being tested in NCT03671369?

Interventions: Safety data collection (following routine vaccination) by a continuous surveillance method..

What is the status of NCT03671369?

NCT03671369 is currently COMPLETED.

Last reviewed 2023-02-23 · How we verify

A Post-marketing Surveillance Study to Assess the Safety of Cervarix (GlaxoSmithKline [GSK] Biologicals' Human Papillomavirus [HPV] -16/18 Vaccine), When Administered According to the Approved Prescribing Information (PI) in Korea

NCT03671369 COMPLETED Results posted

The purpose of this post-marketing surveillance (PMS) study is to collect safety information on the use of Cervarix upon the expanded indication to anal cancer to both women and men (at least 600 Korean women and men) within 30 days after each vaccination dose, when administered according to the approved prescribing information (PI) in Korea in a real health care setting over a period of 4 years.

Details

Lead sponsor	GlaxoSmithKline
Status	COMPLETED
Enrolment	670
Start date	Tue Oct 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Dec 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Neoplasms, Rectal

Interventions

Safety data collection (following routine vaccination) by a continuous surveillance method.

Countries

South Korea